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Abstract. We predict disease-genes relations on the Human Interactome net-
work using a methodology that jointly learns functional and connectivity pat-
terns surrounding proteins. Contrary to other data structures, the Interactome is
characterized by high incompleteness and absence of explicit negative knowl-
edge, which makes predictive tasks particularly challenging. To exploit at best
latent information in the network, we propose an extended version of random
walks, named Random Watcher-Walker (RW 2), which is able to learn rich rep-
resentations of disease genes (or gene products) features. Our method success-
fully compares with the best known system for disease gene prediction, and other
state-of-the-art graph-based methods. We perform sensitivity analysis and apply
perturbations to ensure robustness. In contrast with previous studies, our results
demonstrate that connectivity alone is not sufficient to classify disease-related
genes.
1 Introduction
In the last decades, the evolution of medical knowledge has been supported by aca-
demic research and technological developments, on the one hand providing a continu-
ously growing set of biomedical data and on the other hand revealing a complexity only
perceived until now. In this context, biological networks have become a central hub of
multidisciplinary research [1], to address important challenges on both diagnostic and
therapeutic aspects, such as drug development and disease classification [2][3][4].
Network Medicine [5] (NM) is a relatively recent approach to analyze the complex-
ity of biomolecular structures. NM proposes to exploit the network topology (e.g. the re-
lations among biological entities) and the network dynamics (e.g. the information flow
across the network) to better understand the pathogenic behavior of complex molec-
ular interconnections, that standard reductionist5 approaches cannot detect. A central
finding of NM is the following [5]: ”If a gene or molecule is involved in a specific bio-
chemical process or disease, its direct interactors might also be suspected to have some
5 according to reductionism, a single disease cause can be identified by decoupling the complex
biological or medical phenomenons in multiple components.
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role in the same biochemical process. In line with this ‘local’ hypothesis, proteins that
are involved in the same disease show a high propensity to interact with each other”.
Several studies have been published in support of this hypothesis, such as [6], [7], [8]
and others.
It is important to stress the potential impact of network methods to progress in
this field. In fact, traditional ways to assess the role of genes in diseases involve time-
consuming and extremely expensive6 statistical studies based on sequencing the DNA
of a large number of patients affected by a given disease, known as Genome-Wide
association studies (GWAS). In this context, network science and machine learning
methods can be effective in reducing the number of alternatives to be explored in clinical
experiments.
The objective of this paper is to contribute to the problem of predicting disease-
related genes. We present a graph-based approach, based on an extended notion of ran-
dom walks, to extract topological information and functional properties of local sub-
structures within the human interactome network. Detected patterns are then used to
train a machine learning predictor. Our method advances the state of the art, by suc-
cessfully comparing with the best known system for disease gene prediction, and other
known graph-based methods. Furthermore, our study brings new insight to the subject
matter, showing that connectivity alone is not sufficient to reliably identify disease-
related genes.
2 Related Work
Recent research fields such as System Biology and Network Medicine (NM) [5] has
led to new approaches integrating the so called -omics fields of study (genomics, pro-
teomics and metabolomics) and network science. In these studies, complex physical
and structural interactions between molecules are modeled as a graph structure, called
Interactome. As mentioned in the introduction, the driving idea of NM is that the study
of network topology and dynamics can accelerate discovery of new biological inter-
actions and pathways [9], which in turn will drive progress on disease treatments and
personalized medicine. However, the application of ”standard” graph-based methods to
the human Interactome is complicated by the fact that it is estimated that only 20% of
existing interactions are actually modeled [10]. Another problem is absence of explicit
encoding of negative knowledge: when a relation is not present between two biolog-
ical entities, we don’t know if the relation actually does not exist or if it is still un-
known7. Our intuition is that these specific characteristics of the Interactome network
cause many commonly used graph-mining methods to be ineffective. For example, [11]
and [7] found that community detection algorithms and centrality measures fail to iden-
tify relevant structures. On the other hand, the interest of scientists in NM remains high,
since a growing interdisciplinary effort gives hope for an acceleration of results in this
field.
Disease Gene Prediction (DGP) is a relevant, but still open, research topic, since
the genetic bases of diseases are largely unknown. Currently, only 10% of genes have a
6 https://www.genome.gov/27541954/dna-sequencing-costs-data/
7 This is motivated by the inherent complexity of negative hypothesis testing in this field.
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known association with some disease [5]. Genome-Wide associations studies (GWAS)
have led to the collections of such associations in databases, like OMIM [12] and
DisGenNet [13]. However, as mentioned in the introduction, GWAS studies are very
expensive and labor intensive. Following the categorization in [5], there exist several
interactome-based approaches for the DGP problem, divided into three categories:
1. Linkage Methods: Candidate disease genes (or gene products8) are hypothesized
to have a direct interaction with known disease genes in the interactome. For ex-
ample, in [14] candidate disease genes are identifyed in the direct neighborhood
of known disease genes and then filtered using their chromosomal locations (the
authors check if the chromosomal location falls within one or more ”disease loci”).
2. Module-based Methods: Candidate genes belonging to the same neighborhoods are
more likely to be involved in the same diseases. These approaches are also know as
”disease module-based”, like for example [7,8]. Note that the notions of ”neighbor-
hood” and ”module” are vague here, and standard community detection algorithms
do not work. Both approaches expand disease modules by exploiting the structure
of the network. The main idea of DIAMOnD [7] is based on the use of a connec-
tivity significance measure, designed to take advantage of the weak interconnection
properties of the interactome. Using this metric, DIAMOnD first generates a con-
nection ranking for each node, with respect to a chosen disease module. DIAMOnD
works by iteratively expanding a single disease module with the first ranked node
identified in each iteration. Unlike DIAMOnD, Gladiator [8] considers multiple
disease modules simultaneously. Gladiator is based on the intuition that nodes with
common phenotypes (common sets of symptoms) are also likely to share molecular
mechanisms9. In order to predict gene-disease relationships, Gladiator uses a simu-
lated annealing algorithm that considers both information on phenotypic similarity
and protein interconnection.
3. Diffusion Methods: are ranking approach based on the random-walk technique
[15,16,17,18,19]. For example, in order to find novel disease-gene candidates, [16]
introduce random walk with restart, starting from genes known to be associated
with a given disease.
In this paper, we introduce a fourth category, that we call Representation Learning
Methods, consisting in the use of graph-based methods [20][21] to learn rich represen-
tations of disease genes (or gene products) features, followed by a machine learning
predictor for detecting candidate genes. As an example in this category, we present the
Random Watcher-Walker (RW 2), described in Section 3.
3 Description of the Method
We predict disease genes using a graph-based methodology which jointly learns func-
tional and connectivity patterns surrounding proteins in the human interactome. The
8 in gene prediction literature, proteins are commonly used in place of genes, since each gene
tells the cell how to put together the building blocks for one specific protein. Therefore, studies
in this field consider protein-protein interaction networks in place of genes.
9 One of the problems of Gladiator is that the use of phenotipic information as a predictor of
disease-gene relatedness for multi-factorial diseases is not assessed in literature.
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network model G(V,E) is shown in Figure 1: nodes v ∈ V are proteins, and edges
e(i, j) ∈ E, i, j ∈ V are protein-protein interactions (as derived from three databases:
IntAct [22], BioGrid [23], MINT [24]. This structure is also referred to in literature as
PPI (Protein-Protein Interaction) network10.
In our approach, each node v is further described by a multi-dimensional feature
vector f(v). In the present study, besides diseases (from OMIM [12]), we consider two
additional relevant11 dimensions: tissues (from the The Human Protein Atlas [25]) and
pathways12 (from KEGG [26]). For each dimension, a valued cell in f(v) indicates
that v is related with a given disease, tissue or pathway category, hereafter denoted as
”category label” or label. Category labels are provided in the same datasets (OMIM,
etc.).
Fig. 1: The network model
The methodology to predict disease-related genes is in three steps:
Step 1: Random Watcher Walker: we collect network connectivity patterns using a
novel method, Random Watcher-Walker (RW 2). In RW 2, the walker, when landing
on node v, ”watches” the node features and selects one label at random with uniform
probability in those cells of f(v) that are equals to 1. Next, it ”walks” with uniform
probability to one of v’s neighbors. In this way, random walks embody both functional
features of traversed nodes (pathobiological properties such as related diseases, tissues
and pathways), and structural features (connected proteins in the interactome).
RW 2 can be seen as a label sequence generation where, ve denote the eth node in
the walk, and le denote the selected label of ve. The generation process satisfies the
following distribution:
P (ve = x, le = a|ve−1 = y) =
10 Note that different studies have used different knowledge bases to build the PPI.
11 following the indications of domain experts
12 https://en.wikipedia.org/wiki/Biological pathway
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pi(y, x) · σ(x, a) if (y, x) ∈ E and a is a label of x
0 otherwise
where pi(y, x) is the normalized transition probability between nodes y and x; σ(x, a)
is the normalized probability of selecting the node-label a in f(x).
Note that our Random Watcher Walker approach is meant to exploit one relevant
findings of Network Medicine, the ”modular” structure of diseases in the interactome,
as summarized in Section 2. Furthermore, our intuition is that random walks crossing
nodes associated with disease modules that are either close, or intersect each other in
the interactome, should have similar label subsequences, since they are extracted from a
similar neighborhood. Given the ”loose” notion of neighborhood implemented by ran-
dom walks, similarity patterns might be captured even in presence of highly incomplete
knowledge.
Step 2: Label Embeddings: collected network connectivity patterns are treated as
”contexts” for individual labels, (as shown in Figure 2) much in same way as sentences
are contexts for individual words. Context are used to train a Skip-Gram [27] model
and learn label embeddings (”dense” vector representations of each label). Label em-
beddings are used to enrich the multidimensional feature vector f(v) of each node of G:
valued cells are replaced by the respective embedding vectors, producing the enriched
feature matrix F (v).
Fig. 2: Example of context for the label ”Stomach”
Step 3: Training: feature matricesF (v) are used to train a fully connected neural net-
work (NN) with Softmax activation function, for predicting disease-gene associations
(Figure 3). The system’s output is a (|D| + 1)-dimensional probability vector, where
|D| is the number of considered disease labels and the additional class label is UNK, to
state absence of known disease relations for a given node.
4 Evaluation Methodology
In this section we describe the dataset used for our experiments, the adopted data trans-
formation methodology, and the experimental strategies and setup.
Dataset: As we already remarked, biomedical data suffer from two problems:
– Absence of Negative Instances: Biomedical data are not characterized by negative
instances. Databases usually do not collect the information about the absence of a
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Fig. 3: Training the NN with feature matrices
relationship between a gene and a disease.
– Incompleteness: The high incompleteness of the human interactome (see Section
1) implies that the information to be exploited can be very sparse.
For this reason, evaluating on synthetic data may lead to inconclusive results, since the
generated datasets can hardly satisfy the statistical properties of the real interactome.
In our experiment, for the purpose of comparison, we use the same interactome (PPI)
network used in DIAMOnD [7]. In this network, there are 13458 proteins and 70 dis-
ease categories. Only 1536 nodes are related to at least 1 disease, of which, 766 have
co-morbidities (i.e., they are known to be related to more than one disease). In addition
to information on disease categories, we enrich feature vectors f(v) with information
on 57 tissue types13 and 321 pathways.
Data Transformation: Figure 4 shows, for each node v of the interactome, the enriched
multidimensional feature matrixF (v) (left) and the corresponding ground-truth output
vectors D (right) to be used for training. Dark cells in F (v) represent embedding vec-
tors associated to valued feature labels in the original f(v), while white cells are zero
vectors. The (|D|+ 1)-dimensional ground-truth vector D has the ith cell equal to 1 if
the node is known to be associated to the corresponding disease d ∈ D. The last cell of
this vector is 1 if no diseases are known to be associated to the node.
Clearly, the dataset in Figure 4 cannot be used for training, because the NN would
trivially learn that if a disease vector is valued in F (v), then the corresponding cell of
the output should be 1. To avoid trivial learning, we train the NN using modified feature
matrices , as shown in Figure 5.
1. If a node v is known to be related to a single disease d, Dv : {d}, |Dv| = 1 ,
then the corresponding embedding vector from the feature matrixF (v) is replaced
13 taken from https://www.proteinatlas.org/humanproteome/tissue
Network-based methods for disease-gene prediction 7
Fig. 4: Feature Matrices and ground-truth vectors
Fig. 5: Modified Feature Matrices for the learning phase
with a zero vector. For example, nodes 2), 3) and 5) of Figure 4 are modified as in
Figure 5. Note that in this way a node with no valued cells in the disease dimension
(instances 1 and 2 of Figure 5), can either be ”unknown” - which corresponds to a 1
in the last cell of the ground-truth vector - or known to be related with one disease.
The NN is therefore encouraged to learn distinguishing between these two cases
based on the embedding vectors of the other dimensions, pathways and tissues;
2. If a node v is known to be related to m diseases Dv : {d1, . . . , dm}, |Dv| = m
, then its feature matrix is duplicated into m matrices. Each duplicated matrix is
associated to only one disease dk ∈ Dv . In each duplicated feature matrix F (v)k
we replace the corresponding embedding vector of the associated disease dk with a
zero vector, and we keep only the 1 associated with dk in the related ground-truth
vector. For example, node 4 in Figure 4 is duplicated in 4.a and 4.b in Figure 5.
This encourages the NN to learn also from co-morbidities.
Experimental Strategies: We first adopt a computationally expensive, but unbiased,
strategy (method 1). With method 1, the Random Watcher-Walker RW 2 collects con-
nectivity patterns from a ”degraded” network from which 20% of the information on
node labels has been removed. Node labels are transformed as for in Figure 5. Next, we
learn label embeddings and train the NN network. Note that in method 1, we repeat all
the three steps of the algorithm (random walks, label embedding and NN training) for
each of theK different train/test split of the dataset used during theK-fold evaluation of
the system. We also introduce a less computationally expensive strategy (method 2) in
which the previously described data transformation is performed after label embedding
without degrading the interactome at each fold evaluation. The dataset shown in Figure
5 is used to train the NN with 80% 20% split and 10-fold evaluation (K = 10). How-
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ever, learning the embeddings on the complete Interactome network could potentially
bias the results of the subsequent NN training phase.
Experimental setup: Tables 1 and 2 show the system parameters for our best experi-
ment. Sensitivity to parameters is discussed in Section 5.2.
Random Walk Parameter Value
Label Embedding Length 128
Walk Length 20
Number of random walks per node 100
p 1
q 1
Skip-Gram context window 3
Skip-Gram Epochs 3
Table 1: Model parameters.
NN Parameter Value
Hidden Layer 0
Activation Function Softmax
Loss Binary Cross-entropy
Optimizer Adam
Batch Size 100
Epochs 5
Table 2: Model parameters.
5 Experiments
5.1 Comparison with other methods
Given the previously outlined characteristics of biomedical data, evaluation measures
such as precision, accuracy and f-score are ineffective. In line with other works [7][8]
in this domain, we use Recall@k, the fraction of correctly predicted items at rank k. In
all our experiments, we set the k value of Recall@k to 1, since as explained in Section
1, the intended use of network methods in medicine is to exploit the results with the
highest confidence, to narrow the scope of expensive and labor intensive clinical tests.
We compare our system (trained according to methods 1 and 2, described in Section
4) with:
1. A baseline method which uses only functional information, i.e. the feature vec-
tors f(v) without label embeddings. This corresponds to exploiting only functional
(feature) similarity.
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2. Node2Vec [20] combined with the NN Classifier. Node2Vec (N2V) is a state-of-
the-art random walk algorithm for Node-Embedding generation. Contrary to our
approach, Node2Vec uses a standard random-walk strategy which exploits only the
connectivity patterns of a network. Consequently, Node2Vec generates embeddings
containing only connectivity information.
3. Graph Convolutional Networks (GCN) [21], an inductive semi-supervised method
to classify nodes in a network, based on an efficient variant of convolutional neural
networks, which operates directly on graphs. GCN handle both the functional and
connectivity information of the network but in a completely different way compared
to our method. We test GCN with default parameters (as specified in [21]).
4. DIAMOnD, which is commonly considered the state of art and most cited study
on disease gene prediction (see Section 2). DIAMOnD, like N2V, exploits only
connectivity information.
For all these methods, during the training phase we remove 20% of the information
concerning disease-node relationships, and use these data for testing. Each experiment
is repeated 10 times with different splits of the learning and test set (10-fold cross evalu-
ation). Next, we compute the Recall@1 and average over all folds. Note that computing
Recall@1 for DIAMOnD is not straightforward. In DIAMOnD evaluation experiments,
described in [7], diseases are considered one at the time. For each disease d, they re-
move node-disease associations from a given fraction of nodes N ′d among those known
to be related with d. Next, they apply an iterative method in which, at each iteration,
they add a new node n (the most likely node among those considered) to the current set
of nodes believed to be related to d. In their paper, the authors perform 200 iterations
and lastly they compute the recall, i.e. the fraction of disease nodes retrieved by their
method, among those (N ′d) that were initially removed. Although the authors do not
explicitly set/report a k value for the Recall, we can assume that setting k=1 for their
system is an upper − bound of the real system performances. In our experiments, we
use the software made available by the authors, and adopt exactly the same iterative
methodology, removing 20% of disease-node associations, like for the other compared
methods.
The results of all comparative experiments are shown in Table 3. The first two rows
of Table 3 show the performance of our system. The difference between methods 1 and
2 (see Section 4) is less than 1% and is not statistically significant (p = 0.14). This
was expected, given the very sparse nature of the interactome graph. A comparison
between the two methods was however necessary to exclude any learning bias. Given
the negligible difference between the two methods, the less computationally intensive
method 2 can be adopted instead of method 1.
Table 3 also shows that N2V and GCN perform very poorly: they are unable to
identify patterns that help to predict disease nodes. As a result, they always predict
the majority class (the label ”unknown”) which explains why the STD is zero. For DI-
AMOnD, we report the recall value obtained as previously explained, averaging over
all diseases, different splits, and 200 iterations for each experiment. We remark that
in [7] the reported performance is higher, but limited to two diseases, lysosomal stor-
age diseases and lipid metabolism disorders, that show higher density of the respective
modules. For the purpose of completeness, Table 4 compares RW 2 and DIAMOnD on
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these very same diseases. Furthermore, the authors of [8], in an experiment consider-
ing all diseases (on a slightly different dataset), reported that DIAMOnD was ”able to
recover 13.3% of the removed associations”, which in line with the performance value
(14%) in Table 3.
NN Parameter R@1 STD
RW 2 (method 1) 35% 0.008
RW 2 (method 2) 36% 0.008
Baseline 2% 0.002
N2V 1% 0
GCN 1% 0
DIAMOnD 14%* 0.011
Table 3: Average Recall@1 and standard deviation over 10 folds. *Note that, as explained, for
DIAMOnD the reported performances represent an upper-bound.
Disease Module RW 2 DIAMOnD
lysosomal storage diseases 79% 50%
lipid metabolism disorders 32% 31%
Table 4: Comparison on two diseases
The results of Table 3 seem rather unexpected: none of the considered methods is
able to predict disease nodes, except RW 2 and, with some ”caveat” given the adopted
evaluation procedure, DIAMOnD. The purpose of next Sections is to interpret more
clearly our results.
5.2 Robustness and sensitivity analysis
First off, we perform a robustness test of RW 2, by randomly rewiring edges14, relabel-
ing node features, and both. The result is shown in Table 5. The table shows that while
relabeling severely affects system’s performance, rewiring only results in a 3% points
decrease in performance. Although this difference is statistically significant (p < 0.02),
it clearly shows that connectivity is a weak feature. This is in line with Table 3, that
shows extremely poor performances for methods based only on connectivity patterns
(N2V and GCN).
14 using the method in http://bit.ly/2N0sKHf
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RW 2 (method 2) R@1 STD
Rewiring 33% 0.0086
Relabel 2% 0.0005
Both 1% 0.0003
Table 5: Robustness test: rewiring and relabeling the network
Next, we analyze the network sensitivity to parameters. First, we found that increas-
ing the number of layers of the neural network (step 3 of the pipeline) does not improve
results15. Considering the entire pipeline, only two parameters were found to affect the
performance: the dimension of embedding vectors, and the dimension of the window
(context) used during the label embedding phase. Figure 6 shows that a sufficiently
high number of dimensions are needed (> 100), which is in line with other domains in
which embeddings have been used. Figure 7 shows that best performances are obtained
with smaller left-right contexts (a window size between 1 and 5). This confirms that
the diameter of disease modules (remember that disease modules are vaguely defined
as an ”area” where nodes related to the same disease tend to reside) is relatively small,
in line with other studies, for example [28], stating that the median distance between
components in a module is almost 2.9, and [4] where the diameter of a disease module
is estimated to be 1.8 in the average.
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Fig. 6: Sensitivity analysis: performance as a function of the dimension of embedding vectors.
5.3 Discussion
To summarize, all experiments confirm that connectivity patterns only marginally con-
tribute to identifying gene-disease relationships. This is demonstrated both by the very
15 Although more experiments with different and more complex learners might be needed, our
intuition is that data quality -namely, incompleteness and absence of negative evidence - is too
low for deep methods to learn regularities.
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Fig. 7: Sensitivity analysis: performance as a function of the dimension of Skip-gram context
window
poor performances of methods, such as N2V and GCN, that only exploit connectivity,
and by our robustness tests. Similarly, using only functional features does not produce
relevant results, as shown by the baseline method performance. Instead, RW 2 is able
to discover specific combinations of connectivity and functional features that have a
higher probability of being found in the vicinity of a node related with a given disease.
The scarce contribution of connectivity features to the discovery of disease modules
contradicts previous results in this domain, but is in agreement with a very recent,
although preliminary, study published by a prestigious institution [28] were the au-
thors demonstrate that 90% of disease-related nodes do not correspond to single well-
connected components in the human interactome network. Instead, nodes associated
with a single disease tend to form many separate connected components/regions in the
network. In particular, the authors observe that ”current methods disregard loosely con-
nected proteins when making predictions, causing many disease module components in
the network to remain unnoticed”. Our study confirms this finding, and demonstrates
that RW 2 is a better method to capture common features of such sparse regions: first,
the Random Watcher Walker jointly captures connectivity and functional patterns in the
vicinity of nodes; second, label embeddings allow to optimize the combination of fea-
tures types that are more predictive of each disease. Note that the notion of ”vicinity” in
embedding methods is more relaxed than ”connectivity”, since the relative distance be-
tween two labels is not fixed, but only constrained by the length of the context window.
We also found that performance degrades when the window length exceeds ±5, which
implies that ”some” vicinity among nodes related with the same disease does exist.
6 Conclusions
We have shown that RW 2 is able to learn regularities in complex networks character-
ized by high incompleteness and absence of negative knowledge. Our study, together
with [28], also poses new problems to the Network Medicine field of research. On the
one hand, the data quality of the interactome network seems too low for many popu-
lar and high performing network methods to produce useful results; on the other hand,
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the initial hypotheses of Network Medicine are not denied by our results, since RW 2
shows that some structure in the data indeed exists. Rather, the challenge is to design
effective methods to capture at best such sparse regularities (as we have shown, RW 2
is a promising solution), and secondly, to enrich or combine in a more effective way
different available sources of information. In this work, we use tissues and pathways,
since they are a readily available and sufficiently reliable information, however we plan
to investigate other sources in our future work.
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